menu
    • menu

    Company profile for Incyte Corporation

    NEW Drugs in Dev: 68
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted...
    Incyte's vision is to become a leading biopharmaceutical company by building a proprietary pipeline of novel small molecule drugs for serious unmet medical needs primarily in the area of oncology. The field of oncology is evolving rapidly and transforming how cancer is and will be treated. With a growing pipeline that includes innovative compounds in three major oncology areas -- onco-inflammation, immuno-oncology and targeted therapies -- we believe Incyte is at the center of this transformation in cancer care.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Incyte CorporationUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1801 Augustine Cut-off Wilmington, DE 19803
    Telephone
    Telephone
    +1 1.855.446.2983
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.incyte.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Incyte's Phase 3 frontMIND Tafasitamab Trial Hits PFS Goal
    Incyte's Phase 3 frontMIND Tafasitamab Trial Hits PFS Goal

    13 Jun 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260613831839/en/Results-from-Incytes-Pivotal-Phase-3-frontMIND-Trial-of-Tafasitamab-MonjuviMinjuvi-Combination-Presented-at-the-2026-European-Hematology-Association-EHA-Congress-Plenary-Showed-Prolonged-Progression-Free-Survival

    BUSINESSWIRE
    13 Jun 2026
    Share Share
    Incyte Eyes $2B Deal for Star to Grow Haematology Pipeline
    Incyte Eyes $2B Deal for Star to Grow Haematology Pipeline

    07 Jun 2026

    // REUTERS

    https://www.reuters.com/legal/transactional/incyte-nears-up-2-billion-deal-blood-disorder-biotech-star-ft-reports-2026-06-07/

    REUTERS
    07 Jun 2026
    Share Share
    Mirum and Incyte Report Late-Breaking Ph3 Data for FOP at ENDO
    Mirum and Incyte Report Late-Breaking Ph3 Data for FOP at ENDO

    04 Jun 2026

    // PRESS RELEASE

    https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-and-Incyte-Announce-Pivotal-Late-Breaking-Results-for-Zilurgisertib-in-Fibrodysplasia-Ossificans-Progressiva-Accepted-for-Presentation-at-ENDO-2026/default.aspx

    PRESS RELEASE
    04 Jun 2026
    Share Share
    Tafasitamab Combo Cuts Progression Risk in High-Risk Lymphoma
    Tafasitamab Combo Cuts Progression Risk in High-Risk Lymphoma

    31 May 2026

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/incyte-blood-cancer-drug-combo-reduces-disease-progression-risk-with-high-side-2026-05-30/

    REUTERS
    31 May 2026
    Share Share
    Incyte to Present at Goldman Sachs Healthcare Conference
    Incyte to Present at Goldman Sachs Healthcare Conference

    26 May 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260526552507/en/Incyte-to-Present-at-the-Goldman-Sachs-47th-Annual-Global-Healthcare-Conference

    BUSINESSWIRE
    26 May 2026
    Share Share
    Lilly, BMS, Incyte Strike Deals to Keep AI Momentum Rolling
    Lilly, BMS, Incyte Strike Deals to Keep AI Momentum Rolling

    22 May 2026

    // BIOSPACE

    https://www.biospace.com/deals/lilly-bms-incyte-strike-deals-to-keep-biopharmas-ai-integration-rolling

    BIOSPACE
    22 May 2026
    Share Share

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Incyte Signs $2B Deal to Acquire Star Unit, Challenge Takeda

    Details:

    Under the acquisition of VGA039, an antibody targeting PROS1, the deal aims to advance treatment for Von Willebrand Disease.


    Lead Product(s): VGA039

    Therapeutic Area: Genetic Disease Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Recipient: Star Therapeutics

    Deal Size: $2,000.0 million Upfront Cash: $1,250.0 million

    Deal Type: Acquisition June 08, 2026

    blank

    01

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : VGA039

    Therapeutic Area : Genetic Disease

    Highest Development Status : Phase III

    Recipient : Star Therapeutics

    Deal Size : $2,000.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Incyte Signs $2B Deal to Acquire Star Unit, Challenge Takeda

    Details : Under the acquisition of VGA039, an antibody targeting PROS1, the deal aims to advance treatment for Von Willebrand Disease.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : $1,250.0 million

    June 08, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

    Details:

    INCA033989 is a antibody drug, which is currently being evaluated in Phase III clinical studies for the treatment of thrombocythemia, essential.


    Lead Product(s): INCA033989,PEG interferon Alfa-2a,Ropeginterferon-Alfa-2b

    Therapeutic Area: Hematology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 03, 2026

    blank

    02

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INCA033989,PEG interferon Alfa-2a,Ropeginterferon-Alfa-2b

    Therapeutic Area : Hematology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombo...

    Details : INCA033989 is a antibody drug, which is currently being evaluated in Phase III clinical studies for the treatment of thrombocythemia, essential.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    June 03, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream...

    Details:

    Ruxolitinib is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.


    Lead Product(s): Ruxolitinib Phosphate,Povorcitinib

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 14, 2026

    blank

    03

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ruxolitinib Phosphate,Povorcitinib

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple D...

    Details : Ruxolitinib is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of undisclosed medical condition.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 14, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Incyte Reveals FDA Approval of Jakafi XRTM for Myelofibrosis, Polycythemia Vera, and GVHD

    Details:

    Ruxolitinib, a miscellaneous product targeting Tyrosine-protein kinase JAK1 and JAK2, shows promise in treating Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease.


    Lead Product(s): Ruxolitinib Phosphate

    Therapeutic Area: Oncology Brand Name: Jakafi

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 01, 2026

    blank

    04

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ruxolitinib Phosphate

    Therapeutic Area : Oncology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Incyte Reveals FDA Approval of Jakafi XRTM for Myelofibrosis, Polycythemia Vera, and GVHD

    Details : Ruxolitinib, a miscellaneous product targeting Tyrosine-protein kinase JAK1 and JAK2, shows promise in treating Myelofibrosis, Polycythemia Vera, and Graft-Versus-Host Disease.

    Product Name : Jakafi

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 01, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage...

    Details:

    INCB123667 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of renal insufficiency.


    Lead Product(s): INCB123667

    Therapeutic Area: Nephrology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 30, 2026

    blank

    05

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INCB123667

    Therapeutic Area : Nephrology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult ...

    Details : INCB123667 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of renal insufficiency.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 30, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairmen...

    Details:

    INCB123667 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatic insufficiency.


    Lead Product(s): INCB123667

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 30, 2026

    blank

    06

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INCB123667

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult ...

    Details : INCB123667 is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of hepatic insufficiency.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 30, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Tra...

    Details:

    Azacitidine is a cytotoxic drug drug, which is currently being evaluated in Phase I clinical studies for the treatment of leukemia, myeloid, acute.


    Lead Product(s): Azacitidine,Cyclophosphamide,Mycophenolate Mofetil,Ruxolitinib Phosphate,Tacrolimus

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cytotoxic Drug

    Recipient: OHSU Knight Cancer Institute

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 23, 2026

    blank

    07

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Azacitidine,Cyclophosphamide,Mycophenolate Mofetil,Ruxolitinib Phosphate,Tacrolimus

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : OHSU Knight Cancer Institute

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia...

    Details : Azacitidine is a cytotoxic drug drug, which is currently being evaluated in Phase I clinical studies for the treatment of leukemia, myeloid, acute.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    April 23, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    Details:

    INCB161734 is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of neoplasms.


    Lead Product(s): INCB161734,Oxaliplatin,Calcium Folinate,Irinotecan Hydrochloride,Fluorouracil

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 13, 2026

    blank

    08

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : INCB161734,Oxaliplatin,Calcium Folinate,Irinotecan Hydrochloride,Fluorouracil

    Therapeutic Area : Oncology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mut...

    Details : INCB161734 is a small molecule drug, which is currently being evaluated in Phase III clinical studies for the treatment of neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 13, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

    Details:

    Decitabine is a cytotoxic drug drug, which is currently being evaluated in Phase I clinical studies for the treatment of leukemia, myeloid, acute.


    Lead Product(s): Decitabine,Venetoclax,Axatilimab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Cytotoxic Drug

    Recipient: Northside Hospital

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 06, 2026

    blank

    09

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Decitabine,Venetoclax,Axatilimab

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Recipient : Northside Hospital

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

    Details : Decitabine is a cytotoxic drug drug, which is currently being evaluated in Phase I clinical studies for the treatment of leukemia, myeloid, acute.

    Product Name : Undisclosed

    Product Type : Cytotoxic Drug

    Upfront Cash : Inapplicable

    April 06, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Adagene, Incyte to Evaluate Muzastotug with INCA33890 in MSS CRC

    Details:

    ADG126 (Muzastotug) is a antibody drug, which is currently being evaluated in IND Enabling clinical studies for the treatment of colorectal neoplasms.


    Lead Product(s): AMP945,INCA33890

    Therapeutic Area: Oncology Brand Name: ADG126

    Study Phase: IND EnablingProduct Type: Antibody, Unconjugated

    Recipient: Adagene Suzhou Limited

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration April 02, 2026

    blank

    10

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Incyte Corporation

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AMP945,INCA33890

    Therapeutic Area : Oncology

    Highest Development Status : IND Enabling

    Recipient : Adagene Suzhou Limited

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Adagene, Incyte to Evaluate Muzastotug with INCA33890 in MSS CRC

    Details : ADG126 (Muzastotug) is a antibody drug, which is currently being evaluated in IND Enabling clinical studies for the treatment of colorectal neoplasms.

    Product Name : ADG126

    Product Type : Antibody, Unconjugated

    Upfront Cash : Undisclosed

    April 02, 2026

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search